Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK4 | Q16654 | 1/20 | 0.48 |
| ▸ | EED | O75530 | 3/20 | 0.45 |
| ▸ | RBBP4 | Q09028 | 3/20 | 0.45 |
| ▸ | SUZ12 | Q15022 | 3/20 | 0.45 |
| ▸ | EZH2 | Q15910 | 3/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | GRM1 | Q13255 | 8/20 | 0.44 |
| ▸ | GRM5 | P41594 | 7/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30088583 | 1.00 | PDK4 (0.48) | PDK4EEDRBBP4SUZ12EZH2 | |
| SCHEMBL9933603 | 0.85 | PDK4 (0.51) | PDK4EEDRBBP4SUZ12EZH2 | |
| SCHEMBL19297080 | 0.85 | PDK4 (0.58) | PDK4HTR6JAK1GRM1GRM5 | |
| SCHEMBL30158417 | 0.85 | PDK4 (0.47) | PDK4EEDRBBP4SUZ12EZH2 | |
| SCHEMBL26651022 | 0.85 | PDK4 (0.47) | PDK4EEDRBBP4SUZ12EZH2 | |
| SCHEMBL2425918 | 0.81 | PDK4 (0.48) | PDK4EEDRBBP4SUZ12EZH2 | |
| SCHEMBL2424217 | 0.81 | PDK4 (0.53) | PDK4EEDRBBP4SUZ12EZH2 | |
| SCHEMBL19284668 | 0.81 | PDK4 (0.61) | PDK4HTR6JAK1GRM1GRM5 | |
| SCHEMBL30736543 | 0.79 | PDK4 (0.64) | PDK4HTR6JAK1GRM1GRM5 | |
| SCHEMBL8075949 | 0.79 | PDK4 (0.64) | PDK4HTR6JAK1GRM1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365566-A1 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365566-A1 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2023-11-16 | — | — | US | disclosed |
| CN-115515679-A | Heterocyclic amides and their use for modulating splicing | 雷密克斯医疗公司 | 2022-12-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365566-A1 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | RBM17, HNRNPA1, HNRNPAB | PDK4 2360/4885EED 1697/4885RBBP4 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.